Harvard Bioscience (HBIO) Reaches New 1-Year Low at $2.26
Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $2.26 and last traded at $2.35, with a volume of 6084 shares trading hands. The stock had previously closed at $2.41.
Several analysts recently issued reports on the stock. ValuEngine raised shares of Harvard Bioscience from a “hold” rating to a “buy” rating in a report on Saturday, April 13th. Zacks Investment Research lowered shares of Harvard Bioscience from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. Finally, Janney Montgomery Scott restated a “buy” rating on shares of Harvard Bioscience in a research report on Monday, February 18th.
The stock has a market capitalization of $86.69 million, a P/E ratio of 15.40 and a beta of 1.33. The company has a current ratio of 2.22, a quick ratio of 1.12 and a debt-to-equity ratio of 0.79.
In other Harvard Bioscience news, CEO Jeffrey Duchemin sold 6,332 shares of the company’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $4.50, for a total value of $28,494.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.40% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the business. BNP Paribas Arbitrage SA increased its holdings in shares of Harvard Bioscience by 635.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,567 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 6,538 shares during the period. Parametric Portfolio Associates LLC acquired a new position in shares of Harvard Bioscience in the 1st quarter valued at about $55,000. Kennedy Capital Management Inc. acquired a new position in shares of Harvard Bioscience in the 1st quarter valued at about $97,000. Marshall Wace LLP acquired a new position in shares of Harvard Bioscience in the 3rd quarter valued at about $123,000. Finally, Mackay Shields LLC increased its holdings in shares of Harvard Bioscience by 57.5% in the 4th quarter. Mackay Shields LLC now owns 38,440 shares of the medical instruments supplier’s stock valued at $123,000 after purchasing an additional 14,040 shares during the period. 72.77% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Harvard Bioscience (HBIO) Reaches New 1-Year Low at $2.26” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/harvard-bioscience-hbio-reaches-new-1-year-low-at-2-26/3011415.html.
Harvard Bioscience Company Profile (NASDAQ:HBIO)
Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.
Featured Story: What is an investor looking for in an SEC filing?
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.